Bispecifics Before CAR-T May Be Best-Bet Sequence for Large B-Cell Lymphoma

(MedPage Today) — The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal treatment sequence than BsAb after CAR-T in patients with relapsed or refractory large B-cell lymphoma…